The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
about
Mineralocorticoid Receptor Signaling as a Therapeutic Target for Renal and Cardiac Fibrosis.Clinical Correlates and Prognostic Value of Plasma Galectin-3 Levels in Degenerative Aortic Stenosis: A Single-Center Prospective Study of Patients Referred for Invasive TreatmentGalectin-3 Inhibition Is Associated with Neuropathic Pain Attenuation after Peripheral Nerve InjuryGalectin-3 Blockade Reduces Renal Fibrosis in Two Normotensive Experimental Models of Renal DamageRenal Denervation Findings on Cardiac and Renal Fibrosis in Rats with Isoproterenol Induced Cardiomyopathy.Myocardial Galectin-3 Expression Is Associated with Remodeling of the Pressure-Overloaded Heart and May Delay the Hypertrophic Response without Affecting Survival, Dysfunction, and Cardiac Fibrosis.Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodellingRole for Galectin-3 in Calcific Aortic Valve Stenosis.Beneficial Effects of Galectin-3 Blockade in Vascular and Aortic Valve Alterations in an Experimental Pressure Overload ModelGalectin-3 inhibition prevents adipose tissue remodelling in obesity.Galectin-3 and aldosterone as potential tandem biomarkers in pulmonary arterial hypertension.Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential.Targeting inflammation in diabetic kidney disease: early clinical trials.Plasma galectin-3 levels are associated with the risk of incident chronic kidney disease.Differential Proteomics Identifies Reticulocalbin-3 as a Novel Negative Mediator of Collagen Production in Human Cardiac Fibroblasts.The role of oxidative stress in the crosstalk between leptin and mineralocorticoid receptor in the cardiac fibrosis associated with obesity.Lipoprotein apheresis reduces circulating galectin-3 in humans.Galectin-3 as a novel biomarker for disease diagnosis and a target for therapy (Review).Inhibition of galectin-3 ameliorates the consequences of cardiac lipotoxicity in a rat model of diet-induced obesity.Galectin-3 Activation and Inhibition in Heart Failure and Cardiovascular Disease: An Update.Left atrial volume index in patients with heart failure and severely impaired left ventricular systolic function: the role of established echocardiographic parameters, circulating cystatin C and galectin-3.Synergistic Antioxidant and Anti-Inflammatory Effects between Modified Citrus Pectin and Honokiol.Possible Role of Inflammation and Galectin-3 in Brain Injury after Subarachnoid Hemorrhage.Galectin-3 and prediction of therapeutic response to renal sympathetic denervation.The relation among aldosterone, galectin-3, and myocardial fibrosis: a prospective clinical pilot follow-up study.Aldosterone Impairs Mitochondrial Function in Human Cardiac Fibroblasts via A-Kinase Anchor Protein 12.Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure.Galectin-3 and histological, molecular and biochemical aspects of myocardial fibrosis in heart failure of hypertensive originMineralocorticoid Receptor and Aldosterone-Related Biomarkers of End-Organ Damage in Cardiometabolic Disease
P2860
Q33734806-880AAAB8-110E-4525-9C00-09197794500CQ33754895-10A07225-025E-48EE-8FF8-343F97D96E03Q35922361-848CC8FB-95A0-4967-8C2A-71FEF086099AQ36187612-E23D670A-54E5-422F-9B45-9DC0108B2672Q36392895-41F79676-EB55-498A-9E76-A0B7CDF46072Q36885706-693573AA-D99E-40CC-B78C-927B7352D93AQ37096257-895A121C-6F1A-48A5-9B33-424D0BC34DF3Q37556207-FF14CFE5-75B2-467C-8D3C-32942E1630F2Q38369358-77F68578-2DD9-46A9-8C6A-C17C6E6666CAQ38382993-7AB28743-2323-4F4A-AFB8-E3ABABB12C7AQ38410318-F66508D2-70F6-40BC-ABD2-472EFDAE13B5Q38540889-12B98479-70EF-4DEA-A351-849DBDD221B4Q38857166-D23EDE78-E231-43C9-BC03-344D0D4EED64Q40060474-8DBAC27E-E284-4B58-AE3A-84184C97414CQ42362900-C9182F50-0D3C-4ABB-8447-A6B0A5E34196Q46249649-B0B552C4-BDE2-4B48-BFC8-2C29DAF0FB35Q46290386-678C1346-8167-4CA6-9899-EDF76E3FBDEFQ47329197-D46B6DEA-2C3F-4ECF-A2D7-3DC6D17E3195Q47649685-BD416DF1-3746-4D32-9A56-75CE5DE03F4FQ47653100-4C0EDE9F-DA72-4A94-BBC9-CDF0B25D12EEQ47920631-7FAC7EF3-DA6B-4E89-B886-3D95457CDA03Q48357935-100E514C-C0DE-450E-8FB6-8784F22CB10CQ50133781-438C0337-8724-4E21-B96D-347A5F2168FBQ52852604-6D63F142-822D-4770-8624-6A601139DCC9Q53099098-E6AACE36-5E72-4798-9ED4-B109DBEF8B60Q54979932-A4C6AF8F-623D-4367-8370-DE30F6014145Q55230733-7B9C5C74-63C9-4D45-A4F0-16622F0DBDDFQ57395332-F251C3BD-792B-4EF7-8E28-70E373E1B1A7Q58722306-E5984032-256C-494E-B20D-1ABBFD543846
P2860
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
@en
type
label
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
@en
prefLabel
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries.
@en
P2093
P50
P1433
P1476
The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries
@en
P2093
Elodie Rousseau
Faiez Zannad
Laurent Calvier
Maria Miana
Natalia López-Andrés
Patrick Rossignol
P356
10.1016/J.JCHF.2014.08.002
P577
2014-11-11T00:00:00Z